Lipid-lowering: Can ezetimibe help close the treatment gap?
Ryan C. Neal, MD
Assistant Professor of Medicine, Baylor College of Medicine, Houston, TX
Peter H. Jones, MD
Associate Professor of Medicine, Baylor College of Medicine, Houston, TX
Address: Ryan C. Neal, MD, Assistant Professor of Medicine, Baylor College of Medicine, 6565 Fannin, Suite B160 A, Mailstop A601, Houston, TX 77030; E-mail: email@example.com
Dr. Neal has indicated that he is on the speakers’ bureaus of AstraZeneca Pharmaceuticals, Merck, and Schering Plough companies and has received grant or research support from Astra Zeneca and Kos Pharmaceuticals, Inc.
Dr. Jones has indicated that he has received grant or research support from the Pfizer, AstraZeneca, and GlaxoSmithKline companies.
ABSTRACTMost patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.